ELOX

NASDAQ 已收盘

Eloxx Pharmaceuticals

10.69 USD
▲+0.04+0.38%
盘后 10.67 -0.19%
2026-11-20
市值
$43.15M
市盈率
—
EPS
-2.46
股息率
—
52 周区间
0.00 – 23.40
成交量
14.98K
Beta
-169223.47
目标价
37.50
52W 低 0.0052W 高 23.40
价格走势

公司简介

Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates that modulate the ribosome and promote readthrough of premature stop codons caused by nonsense mutations in the United States, Israel, and Australia. The company is developing exaluren, a eukaryotic ribosome-selective glycoside in a Phase 2 trial for the treatment of rare kidney diseases, including Alport syndrome with nonsense mutations, cystic fibrosis with nonsense mutations, and nephropathic cystinosis with nonsense mutations,...